HotSpot Therapeutics

Unlocking nature's regulatory mechanisms to advance allosteric drug discovery

[HotSpot Therapeutics @hotspotthera]

Great connecting with the immunology community this weekend at #EULAR2026!

Thank you to everyone who stopped by our poster, and we look forward to continuing to engage with the scientific community as we advance our IRF5 inhibitor program!

[HotSpot Therapeutics @hotspotthera]

We’re excited to highlight that preclinical data from our small molecule IRF5 inhibitor program will be featured at #EULAR2026. Swing by our poster on Saturday if you’re in London, and check out our press release to learn more: https://t.co/vjY45XaHFP

[HotSpot Therapeutics @hotspotthera]

HotSpot Therapeutics is heading to #EULAR2026 on Saturday, June 6 to present preclinical data from our small molecule IRF5 inhibitor program. We hope to see you soon in London! https://t.co/h0di0qxyyz

[HotSpot Therapeutics @hotspotthera]

On #WorldLupusDay, we’re recognizing the millions of people worldwide living with lupus, as well as the families, clinicians, and advocates working to improve awareness, care, and outcomes. We’re proud to stand with the World Lupus Federation’s call to #MakeLupusVisible.

[HotSpot Therapeutics @hotspotthera]

In his latest blog post, Jonathan Montagu, CEO of HotSpot, explores the risks and rewards of drug development in China from the perspective of a US-based biopharma — and why the question may no longer be whether to engage, but how. Read more: https://t.co/un3kxOFaSQ

[HotSpot Therapeutics @hotspotthera]

Thank you to everyone who stopped by our poster today at the 15th European Lupus Meeting! We appreciated the opportunity to connect and engage with the scientific community around our preclinical IRF5 inhibitor data.

[HotSpot Therapeutics @hotspotthera]

The HotSpot team has touched down in Lisbon, where we will be presenting new preclinical data from our small molecule IRF5 inhibitor program at the 15th European Lupus Meeting! Swing by our poster this Friday or check out our press release to learn more: https://t.co/8lihNmWxE9

[HotSpot Therapeutics @hotspotthera]

We’re excited to head to Lisbon for the 15th European Lupus Meeting! HotSpot Therapeutics will present new preclinical data from our small molecule IRF5 inhibitor program.

If you’re attending, please stop by our poster — we’d love to connect.

https://t.co/tbEoKCza2O

[HotSpot Therapeutics @hotspotthera]

HotSpotters’ talents transcend well beyond the lab and all the way into the kitchen! What a delicious spread at our annual holiday potluck. Thanks to everyone who brought a dish and joined the fun!

[HotSpot Therapeutics @hotspotthera]

Check out the latest blog post from our CEO, Jonathan Montagu, where he reflects on the lessons learned from navigating challenging market conditions, ranging from earlier days in his career to the current environment: https://t.co/dUICMFe6ZT

[HotSpot Therapeutics @hotspotthera]

Thank you to our summer intern, Alina Pucci, for her help this summer! We wish her all the best as she heads back to college. And a special shout-out to Varuna for her mentorship!

[HotSpot Therapeutics @hotspotthera]

The HotSpot team took to the harbor for our annual summer outing to celebrate a year of hard work… And even got to spot our offices in the background! What a fun day on the water.

[HotSpot Therapeutics @hotspotthera]

A “complex” solution to a “complex” problem? Check out our latest blog post that explores a potential approach to attacking KRAS G12X colorectal cancer via the CBM signalosome complex: https://t.co/3GBuCLmQa0

[HotSpot Therapeutics @hotspotthera]

HotSpot team members are celebrating the holiday weekend presenting preclinical data from our CBM signalosome inhibitor program at ESMO GI, demonstrating its potential for the treatment of KRASG12X CRC. Check out our press release to learn more! https://t.co/MNSFbrPmRB

[HotSpot Therapeutics @hotspotthera]

The HotSpot team is thrilled to be on the ground at ESMO GI presenting preclinical data from our CBM signalosome inhibitor program. Check out our posters this Fri., Jul. 4, 15:30 CEST if you’re in Barcelona!

[HotSpot Therapeutics @hotspotthera]

This afternoon, the HotSpot team presented encouraging preclinical data for our IRF5 program, supporting the potential of a potent and selective small molecule IRF5 inhibitor for a range of autoimmune diseases. Check out our press release to learn more! https://t.co/wh5MU0bBiy

[HotSpot Therapeutics @hotspotthera]

Today at #FOCIS2025, the HotSpot team will be presenting preclinical data from our small molecule IRF5 inhibitor program. Check out the presentation at 4:00 PM ET or stop by the poster if you’re in Boston today!

[HotSpot Therapeutics @hotspotthera]

In our latest blog post, our CEO, Jonathan Montagu, explores the therapeutic promise of targeting transcription factors and highlights the growing wave of scientific innovations that are beginning to enable the drugging of this target class. Check it out: https://t.co/vHLwJpC6k6

[Bruce Booth @LifeSciVC]

"A New Wave of Therapeutic Innovation Through Targeting Transcription Factors"

New blog post from @JDMontagu CEO of @hotspotthera, highlighting IRF5 among others

https://t.co/ctMXMUytgK

[HotSpot Therapeutics @hotspotthera]

The HotSpot team gathered for a potluck to enjoy foods ranging from smoked turkey to eggplant lasagna to sesame balls. What a treat to experience such a range of cooking and to come together ahead of the Thanksgiving Day holiday!

[HotSpot Therapeutics @hotspotthera]

This weekend, we will be presenting additional biomarker data from the Phase 1 study of HST-1011, our novel CBL-B inhibitor, at #SITC24. Check out our press release to learn more and stop by the poster Saturday if you’re in Houston! https://t.co/mbHQR4fmYG